Mulay James 4
4 · CG Oncology, Inc. · Filed Sep 22, 2025
Insider Transaction Report
Form 4
Mulay James
Director
Transactions
- Exercise/Conversion
Common Stock
2025-09-19$1.82/sh+3,574$6,505→ 3,574 total - Exercise/Conversion
Director Stock Option (right to buy)
2025-09-18−19,112→ 16,329 totalExercise: $1.82Exp: 2031-07-18→ Common Stock (19,112 underlying) - Exercise/Conversion
Common Stock
2025-09-18$1.82/sh+19,112$34,784→ 19,112 total - Sale
Common Stock
2025-09-18$39.01/sh−19,112$745,559→ 0 total - Sale
Common Stock
2025-09-19$38.99/sh−3,574$139,350→ 0 total - Exercise/Conversion
Director Stock Option (right to buy)
2025-09-19−3,574→ 12,755 totalExercise: $1.82Exp: 2031-07-18→ Common Stock (3,574 underlying)
Footnotes (3)
- [F1]The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.99 to $39.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Fully vested